13 results on '"Kobinger, Gary P."'
Search Results
2. Impact of intensive care unit supportive care on the physiology of Ebola virus disease in a universally lethal non-human primate model
- Author
-
Poliquin, Guillaume, Funk, Duane, Jones, Shane, Tran, Kaylie, Ranadheera, Charlene, Hagan, Mable, Tierney, Kevin, Grolla, Allen, Dhaliwal, Amrinder, Bello, Alexander, Leung, Anders, Nakamura, Cory, Kobasa, Darwyn, Falzarano, Darryl, Garnett, Lauren, Bovendo, Hugues Fausther, Feldmann, Heinz, Kesselman, Murray, Hansen, Gregory, Gren, Jason, Risi, George, Biondi, Mia, Mortimer, Todd, Racine, Trina, Deschambault, Yvon, Aminian, Sam, Edmonds, Jocelyn, Sourette, Ray, Allan, Mark, Rondeau, Lauren, Hadder, Sharron, Press, Christy, DeGraff, Christine, Kucas, Stephanie, Cook, Bradley W. M., Hancock, B. J., Kumar, Anand, Soni, Reeni, Schantz, Darryl, McKitrick, Jarrid, Warner, Bryce, Griffin, Bryan D., Qiu, Xiangguo, Kobinger, Gary P., Safronetz, Dave, Stein, Derek, Cutts, Todd, Kenny, James, Soule, Geoff, Kozak, Robert, Theriault, Steven, Menec, Liam, Vendramelli, Robert, Higgins, Sean, Liu, Guodong, Rahim, Niaz Md, Kasloff, Samantha, Sloan, Angela, He, Shihua, Tailor, Nikesh, Gray, Michael, and Strong, James E.
- Published
- 2019
- Full Text
- View/download PDF
3. Intradermal SynCon® Ebola GP DNA Vaccine Is Temperature Stable and Safely Demonstrates Cellular and Humoral Immunogenicity Advantages in Healthy Volunteers.
- Author
-
Tebas, Pablo, Kraynyak, Kimberly A, Patel, Ami, Maslow, Joel N, Morrow, Matthew P, Sylvester, Albert J, Knoblock, Dawson, Gillespie, Elisabeth, Amante, Dinah, Racine, Trina, McMullan, Trevor, Jeong, Moonsup, Roberts, Christine C, Park, Young K, Boyer, Jean, Broderick, Kate E, Kobinger, Gary P, Bagarazzi, Mark, Weiner, David B, and Sardesai, Niranjan Y
- Subjects
DNA vaccines ,HUMORAL immunity ,CLINICAL trial registries ,EBOLA virus ,VOLUNTEERS ,INTERLEUKIN-12 - Abstract
Background: Nonlive vaccine approaches that are simple to deliver and stable at room temperature or 2-8°C could be advantageous in controlling future Ebola virus (EBOV) outbreaks. Using an immunopotent DNA vaccine that generates protection from lethal EBOV challenge in small animals and nonhuman primates, we performed a clinical study to evaluate both intramuscular (IM) and novel intradermal (ID) DNA delivery.Methods: Two DNA vaccine candidates (INO-4201 and INO-4202) targeting the EBOV glycoprotein (GP) were evaluated for safety, tolerability, and immunogenicity in a phase 1 clinical trial. The candidates were evaluated alone, together, or in combination with plasmid-encoded human cytokine interleukin-12 followed by in vivo electroporation using either the CELLECTRA® IM or ID delivery devices.Results: The safety profile of all 5 regimens was shown to be benign, with the ID route being better tolerated. Antibodies to EBOV GP were generated by all 5 regimens with the fastest and steepest rise observed in the ID group. Cellular immune responses were generated with every regimen.Conclusions: ID delivery of INO-4201 was well tolerated and resulted in 100% seroreactivity after 2 doses and elicited interferon-γ T-cell responses in over 70% of subjects, providing a new approach for EBOV prevention in diverse populations. Clinical Trials Registration. NCT02464670. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
4. Implementation of Objective PASC-Derived Taxon Demarcation Criteria for Of?cial Classi?cation of Filoviruses.
- Author
-
Yĺmíng Bào, Amarasinghe, Gaya K., Basler, Christopher F., Bavari, Sina, Bukreyev, Alexander, Chandran, Kartik, Dolnik, Olga, Dye, John M., Ebihara, Hideki, Formenty, Pierre, Hewson, Roger, Kobinger, Gary P., Leroy, Eric M., Mühlberger, Elke, Netesov, Sergey V., Patterson, Jean L., Paweska, Janusz T., Smither, Sophie J., Ayato Takada, and Towner, Jonathan S.
- Subjects
FILOVIRIDAE ,TECHNICAL specifications ,SPECIES ,GENETICS ,EBOLA virus - Abstract
The mononegaviral family Filoviridae has eight members assigned to three genera and seven species. Until now, genus and species demarcation were based on arbitrarily chosen filovirus genome sequence divergence values ( 50% for genera, 30% for species) and arbitrarily chosen phenotypic virus or virion characteristics. Here we report filovirus genome sequence-based taxon demarcation criteria using the publicly accessible PAirwise Sequencing Comparison (PASC) tool of the US National Center for Biotechnology Information (Bethesda, MD, USA). Comparison of all available filovirus genomes in GenBank using PASC revealed optimal genus demarcation at the 55-58% sequence diversity threshold range for genera and at the 23-36% sequence diversity threshold range for species. Because these thresholds do not change the current official filovirus classification, these values are now implemented as filovirus taxon demarcation criteria that may solely be used for filovirus classification in case additional data are absent. A near-complete, coding-complete, or complete filovirus genome sequence will now be required to allow official classification of any novel "filovirus." Classification of filoviruses into existing taxa or determining the need for novel taxa is now straightforward and could even become automated using a presented algorithm/flowchart rooted in RefSeq (type) sequences. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
5. Structures of protective antibodies reveal sites of vulnerability on Ebola virus.
- Author
-
Murin, Charles D., Fusco, Marnie L., Bornholdt, Zachary A., Xiangguo Qiu, Olinger, Gene G., Zeitlin, Larry, Kobinger, Gary P., Ward, Andrew B., and Saphire, Erica Ollmann
- Subjects
EBOLA virus disease ,FILOVIRIDAE ,PRIMATES as laboratory animals ,MONOCLONAL antibodies ,GLYCOPROTEINS ,PANDEMICS - Abstract
Ebola virus (EBOV) and related filoviruses cause severe hemorrhagic fever, with up to 90% lethality, and no treatments are approved for human use. Multiple recent outbreaks of EBOV and the likelihood of future human exposure highlight the need for pre- and postexposure treatments. Monoclonal antibody (mAb) cocktails are particularly attractive candidates due to their proven postexposure efficacy in nonhuman primate models of EBOV infection. Two candidate cocktails, MB-003 and ZMAb, have been extensively evaluated in both in vitro and in vivo studies. Recently, these two therapeutics have been combined into a new cocktail named ZMapp, which showed increased efficacy and has been given compassionately to some human patients. Epitope information and mechanism of action are currently unknown for most of the component mAbs. Here we provide single-particle EM reconstructions of every mAb in the ZMapp cocktail, as well as additional antibodies from MB-003 and ZMAb. Our results illuminate key and recurring sites of vulnerability on the EBOV glycoprotein and provide a structural rationale for the efficacy of ZMapp. Interestingly, two of its components recognize overlapping epitopes and compete with each other for binding. Going forward, this work now provides a basis for strategic selection of next-generation antibody cocktails against Ebola and related viruses and a model for predicting the impact of ZMapp on potential escape mutations in ongoing or future Ebola outbreaks. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
6. Characterization of host immune responses in Ebola virus infections.
- Author
-
Wong, Gary, Kobinger, Gary P, and Qiu, Xiangguo
- Subjects
EBOLA virus disease ,HEMORRHAGIC fever ,NATURAL immunity ,IMMUNOREGULATION ,DISEASE risk factors - Abstract
Ebola causes highly lethal hemorrhagic fever in humans with no licensed countermeasures. Its virulence can be attributed to several immunoevasion mechanisms: an early inhibition of innate immunity started by the downregulation of type I interferon, epitope masking and subversion of the adaptive humoural immunity by secreting a truncated form of the viral glycoprotein. Deficiencies in specific and non-specific antiviral responses result in unrestricted viral replication and dissemination in the host, causing death typically within 10 days after the appearance of symptoms. This review summarizes the host immune response to Ebola infection, and highlights the short- and long-term immune responses crucial for protection, which holds implications for the design of future vaccines and therapeutics. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
7. Chimpanzee adenovirus vaccine protects against Zaire Ebola virus
- Author
-
Kobinger, Gary P., Feldmann, Heinz, Zhi, Yan, Schumer, Gregory, Gao, Guangping, Feldmann, Friederike, Jones, Steven, and Wilson, James M.
- Subjects
- *
CHIMPANZEES as laboratory animals , *ADENOVIRUSES , *GUINEA pigs , *EBOLA virus disease , *GLYCOPROTEINS , *VACCINATION - Abstract
Abstract: This study evaluated the use of a chimpanzee-based adenovirus vaccine in mouse and Guinea pigs models of Zaire Ebola virus (ZEBOV) infection. Vaccine vector expressing the envelope glycoprotein of ZEBOV was created from the molecular clone of chimpanzee adenovirus pan7 (AdC7). AdC7 vaccine stimulated robust T and B cell responses to ZEBOV in naïve mice inducing complete protection to an otherwise lethal challenge of ZEBOV. Complete protection to Zaire Ebola virus was also observed in Guinea pigs vaccinated with a relatively low dose of AdC7 (5 × 109/kg). Pre-existing immunity to AdHu5 was generated in mice following pre-exposure to AdHu5 or administration of pooled human immune globulin. Pre-existing immunity to human adenoviruses severely compromised the efficacy of the human AdHu5 vaccine but not the chimpanzee AdC7 vaccine. These results validate further development of Chimpanzee-based vaccine and highlight the impact of pre-existing immunity to the vaccine carrier. [Copyright &y& Elsevier]
- Published
- 2006
- Full Text
- View/download PDF
8. Nomenclature- and Database-Compatible Names for the Two Ebola Virus Variants that Emerged in Guinea and the Democratic Republic of the Congo in 2014
- Author
-
Kuhn, Jens H., Andersen, Kristian G., Baize, Sylvain, Bào, Yīmíng, Bavari, Sina, Berthet, Nicolas, Blinkova, Olga, Brister, J. Rodney, Clawson, Anna N., Fair, Joseph, Gabriel, Martin, Garry, Robert F., Gire, Stephen K., Goba, Augustine, Gonzalez, Jean-Paul, Günther, Stephan, Happi, Christian T., Jahrling, Peter B., Kapetshi, Jimmy, Kobinger, Gary, Kugelman, Jeffrey R., Leroy, Eric M., Maganga, Gael Darren, Mbala, Placide K., Moses, Lina M., Muyembe-Tamfum, Jean-Jacques, N’Faly, Magassouba, Nichol, Stuart T., Omilabu, Sunday A., Palacios, Gustavo, Park, Daniel J., Paweska, Janusz T., Radoshitzky, Sheli R., Rossi, Cynthia A., Sabeti, Pardis C., Schieffelin, John S., Schoepp, Randal J., Sealfon, Rachel, Swanepoel, Robert, Towner, Jonathan S., Wada, Jiro, Wauquier, Nadia, Yozwiak, Nathan L., and Formenty, Pierre
- Subjects
Ebola ,Ebola virus ,ebolavirus ,filovirid ,filovirus ,genome annotation ,Lomela ,Lokolia ,Makona ,mononegavirad ,mononegavirus ,virus classification ,virus isolate ,virus nomenclature ,virus strain ,virus taxonomy ,virus variant - Abstract
In 2014, Ebola virus (EBOV) was identified as the etiological agent of a large and still expanding outbreak of Ebola virus disease (EVD) in West Africa and a much more confined EVD outbreak in Middle Africa. Epidemiological and evolutionary analyses confirmed that all cases of both outbreaks are connected to a single introduction each of EBOV into human populations and that both outbreaks are not directly connected. Coding-complete genomic sequence analyses of isolates revealed that the two outbreaks were caused by two novel EBOV variants, and initial clinical observations suggest that neither of them should be considered strains. Here we present consensus decisions on naming for both variants (West Africa: “Makona”, Middle Africa: “Lomela”) and provide database-compatible full, shortened, and abbreviated names that are in line with recently established filovirus sub-species nomenclatures.
- Published
- 2014
- Full Text
- View/download PDF
9. Filovirus RefSeq Entries: Evaluation and Selection of Filovirus Type Variants, Type Sequences, and Names
- Author
-
Kuhn, Jens H., Andersen, Kristian G., Bào, Yīmíng, Bavari, Sina, Becker, Stephan, Bennett, Richard S., Bergman, Nicholas H., Blinkova, Olga, Bradfute, Steven, Brister, J. Rodney, Bukreyev, Alexander, Chandran, Kartik, Chepurnov, Alexander A., Davey, Robert A., Dietzgen, Ralf G., Doggett, Norman A., Dolnik, Olga, Dye, John M., Enterlein, Sven, Fenimore, Paul W., Formenty, Pierre, Freiberg, Alexander N., Garry, Robert F., Garza, Nicole L., Gire, Stephen K., Gonzalez, Jean-Paul, Griffiths, Anthony, Happi, Christian T., Hensley, Lisa E., Herbert, Andrew S., Hevey, Michael C., Hoenen, Thomas, Honko, Anna N., Ignatyev, Georgy M., Jahrling, Peter B., Johnson, Joshua C., Johnson, Karl M., Kindrachuk, Jason, Klenk, Hans-Dieter, Kobinger, Gary, Kochel, Tadeusz J., Lackemeyer, Matthew G., Lackner, Daniel F., Leroy, Eric M., Lever, Mark S., Mühlberger, Elke, Netesov, Sergey V., Olinger, Gene G., Omilabu, Sunday A., Palacios, Gustavo, Panchal, Rekha G., Park, Daniel J., Patterson, Jean L., Paweska, Janusz T., Peters, Clarence J., Pettitt, James, Pitt, Louise, Radoshitzky, Sheli R., Ryabchikova, Elena I., Saphire, Erica Ollmann, Sabeti, Pardis C., Sealfon, Rachel, Shestopalov, Aleksandr M., Smither, Sophie J., Sullivan, Nancy J., Swanepoel, Robert, Takada, Ayato, Towner, Jonathan S., van der Groen, Guido, Volchkov, Viktor E., Volchkova, Valentina A., Wahl-Jensen, Victoria, Warren, Travis K., Warfield, Kelly L., Weidmann, Manfred, and Nichol, Stuart T.
- Subjects
Bundibugyo virus ,cDNA clone ,cuevavirus ,Ebola ,Ebola virus ,ebolavirus ,filovirid ,filovirus ,genome annotation ,ICTV ,International Committee on Taxonomy of Viruses ,Lloviu virus ,Marburg virus ,marburgvirus ,mononegavirad ,mononegavirus ,Ravn virus ,RefSeq ,Reston virus ,reverse genetics ,Sudan virus ,Taï Forest virus ,virus classification ,virus isolate ,virus nomenclature ,virus strain ,virus taxonomy ,virus variant - Abstract
Sequence determination of complete or coding-complete genomes of viruses is becoming common practice for supporting the work of epidemiologists, ecologists, virologists, and taxonomists. Sequencing duration and costs are rapidly decreasing, sequencing hardware is under modification for use by non-experts, and software is constantly being improved to simplify sequence data management and analysis. Thus, analysis of virus disease outbreaks on the molecular level is now feasible, including characterization of the evolution of individual virus populations in single patients over time. The increasing accumulation of sequencing data creates a management problem for the curators of commonly used sequence databases and an entry retrieval problem for end users. Therefore, utilizing the data to their fullest potential will require setting nomenclature and annotation standards for virus isolates and associated genomic sequences. The National Center for Biotechnology Information’s (NCBI’s) RefSeq is a non-redundant, curated database for reference (or type) nucleotide sequence records that supplies source data to numerous other databases. Building on recently proposed templates for filovirus variant naming [
( )/ / / / - ], we report consensus decisions from a majority of past and currently active filovirus experts on the eight filovirus type variants and isolates to be represented in RefSeq, their final designations, and their associated sequences. - Published
- 2014
- Full Text
- View/download PDF
10. Ebola virus disease complicated with viral interstitial pneumonia: a case report.
- Author
-
Petrosillo, Nicola, Nicastri, Emanuele, Lanini, Simone, Capobianchi, Maria Rosaria, Di Caro, Antonino, Antonini, Mario, Puro, Vincenzo, Lauria, Francesco Nicola, Shindo, Nakono, Magrini, Nicola, Kobinger, Gary P., Ippolito, Giuseppe, and INMI EBOV Team
- Abstract
Background: In the current Ebola epidemic in Western Africa, many healthcare workers have become infected. Some of these have been medically evacuated to hospitals in Europe and the USA. These clinical experiences provide unique insights into the course of Ebola virus disease under optimized condition within high level isolation units.Case Presentation: A 50-year-old Caucasian male physician contracted Ebola virus diseases in Sierra Leone and was medically evacuated to Italy. Few days after the admission the course of the illness was characterized by severe gastro-intestinal symptoms followed by respiratory failure, accompanied by pulmonary infiltration and high Ebola viral load in the bronchial aspirate and Plasmodium vivax co-infection. The patient received experimental antiviral therapy with favipiravir, convalescent plasma and ZMAb. Ebola viral load started to steadily decrease in the blood after ZMAb administration and became undetectable by day 19 after admission, while it persisted longer in urine samples. No temporal association was observed between viral load decay in plasma and administration of favipiravir. The patient completely recovered and was discharged 39 days after admission.Conclusions: This is the first case of Ebola-related interstitial pneumonia documented by molecular testing of lung fluid specimens. This reports underlines the pivotal role of fluid replacement and advanced life support with mechanical ventilation in the management of patients with Ebola virus diseases respiratory failure. Beside our finding indicates a close temporal association between administration of cZMAb and Ebola virus clearance from blood. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
11. Immunization with vesicular stomatitis virus vaccine expressing the Ebola glycoprotein provides sustained long-term protection in rodents.
- Author
-
Wong, Gary, Audet, Jonathan, Fernando, Lisa, Fausther-Bovendo, Hugues, Alimonti, Judie B., Kobinger, Gary P., and Qiu, Xiangguo
- Subjects
- *
VESICULAR stomatitis , *VIRAL vaccines , *EBOLA virus disease , *HEMORRHAGIC fever , *IMMUNIZATION , *GLYCOPROTEINS , *LABORATORY rodents , *EPIDEMICS , *VACCINATION - Abstract
Ebola virus (EBOV) infections cause lethal hemorrhagic fever in humans, resulting in up to 90% mortality. EBOV outbreaks are sporadic and unpredictable in nature; therefore, a vaccine that is able to provide durable immunity is needed to protect those who are at risk of exposure to the virus. This study assesses the long-term efficacy of the vesicular stomatitis virus (VSV)-based vaccine (VSVΔG/EBOVGP) in two rodent models of EBOV infection. Mice and guinea pigs were first immunized with 2 × 10 4 or 2 × 10 5 plaque forming units (PFU) of VSVΔG/EBOVGP, respectively. Challenge of mice with a lethal dose of mouse-adapted EBOV (MA-EBOV) at 6.5 and 9 months after vaccination provided complete protection, and 80% (12 of 15 survivors) protection at 12 months after vaccination. Challenge of guinea pigs with a lethal dose of guinea pig-adapted EBOV (GA-EBOV) at 7, 12 and 18 months after vaccination resulted in 83% (5 of 6 survivors) at 7 months after vaccination, and 100% survival at 12 and 18 months after vaccination. No weight loss or clinical signs were observed in the surviving animals. Antibody responses were analyzed using sera from individual rodents. Levels of EBOV glycoprotein-specific IgG antibody measured immediately before challenge appeared to correlate with protection. These studies confirm that vaccination with VSVΔG/EBOVGP is able to confer long-term protection against Ebola infection in mice and guinea pigs, and support follow-up studies in non-human primates. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
12. Post-exposure therapy of filovirus infections.
- Author
-
Wong, Gary, Xiangguo Qiu, Olinger, Gene G., and Kobinger, Gary P.
- Subjects
- *
VIRUS diseases , *FILOVIRIDAE , *HEMORRHAGIC fever , *MONOCLONAL antibodies , *SYMPTOMS , *MICROBIAL virulence , *DISEASE progression - Abstract
Filovirus infections cause fatal hemorrhagic fever characterized by the initial onset of general symptoms before rapid progression to severe disease; the most virulent species can cause death to susceptible hosts within 10 days after the appearance of symptoms. Before the advent of monoclonal antibody (mAb) therapy, infection of nonhuman primates (NHPs) with the most virulent filovirus species was fatal if interventions were not administered within minutes. A novel nucleoside analogue, BCX4430, has since been shown to also demonstrate protective efficacy with a delayed treatment start. This review summarizes and evaluates the potential of current experimental candidates for treating filovirus disease with regard to their feasibility and use in the clinic, and assesses the most promising strategies towards the future development of a pan-filovirus medical countermeasure. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
13. Intranasal immunization with an adenovirus vaccine protects guinea pigs from Ebola virus transmission by infected animals.
- Author
-
Wong, Gary, Richardson, Jason S., Cutts, Todd, Qiu, Xiangguo, and Kobinger, Gary P.
- Subjects
- *
VIRAL vaccines , *EBOLA viral disease transmission , *ADENOVIRUSES , *DRUG dosage , *INTRAMUSCULAR injections , *DRUG efficacy , *GUINEA pigs as laboratory animals , *EBOLA virus disease prevention - Abstract
Experimental Ebola virus (EBOV) vaccines have previously been shown to protect animals against a high dose intramuscular (IM) challenge, which is seen as a stringent challenge model. However, the protective efficacy against other modes of infection, such as contact with infectious hosts, is unknown. Using a previously established EBOV transmission animal model, we evaluated the efficacy of an adenovirus-based EBOV vaccine given to guinea pigs (gps) 4 weeks before direct contact with untreated, infectious animals. Prior vaccination resulted in robust levels of EBOV-specific antibodies and conferred complete protection in gps. These results support the use of vaccines to prevent EBOV transmission between hosts. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.